Decreased Plsma Visfatin Concentrations in Women With Gestational Diabetes Mellitus

Chan, Te-Fu; Chen, Yi‐Ling; Lee, Chien-Hung; Chou, Fan‐Hao; Wu, Lee-Chen; Jong, Shiang-Bin; Tsai, Eing‐Mei

doi:10.1016/j.jsgi.2006.04.007

Cited by 112 publications

(93 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, mathematical models (HOMA vs IRI) used to calculate IR indices in pregnancy may give discrepant results, and thereby a relationship between visfatin and calculated IR indices. Very recently, unlike our findings and those by Krzyzanowska et al [9], Chan et al [10] have reported lower visfatin levels in women of Chinese origin with GDM. The precise reason for these differences is unclear.…”

Section: Discussioncontrasting

confidence: 99%

“…However, the study design by Chan et al was different: the time of GDM testing was about 24 instead of 28 weeks; different criteria were used to diagnose GDM; and no fasting or post-OGTT glucose values or insulin resistance parameters were assessed in their study. Furthermore, subjects of Far Eastern origin have significant differences in insulin sensitivity in comparison with subjects of Europid origin [11], and therefore it is not possible to directly compare the results of our study with the study by Chan et al [10].…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis Concentrations of visfatin are increased in insulin-resistant conditions, but the relationship between visfatin and insulin and/or insulin resistance indices in pregnancy remains unclear. Insulin resistance in pregnancy is further accentuated in women with gestational diabetes mellitus (GDM). Thus we assessed serum levels of visfatin in pregnant women with varying degrees of glucose tolerance. Materials and methods Fasting visfatin levels were measured at 28 weeks of gestation in 51 women divided according to their response to a 50-g glucose challenge test (GCT) and a 75-g OGTT: control subjects (n=20) had normal responses to both a GCT and an OGTT; the intermediate group (IG; n=15) had a false-positive GCT, but a normal OGTT; the GDM group (n=16) had abnormal GCTs and OGTTs. Results There were no age or BMI differences between analysed groups. Across the subgroups there was a progressive increase in glucose and insulin at 120 min of the OGTT (p<0.01). This was accompanied by an increase in visfatin, from 76.8±14.1 ng/ml in the control subjects, to 84.0±14.7 ng/ml in the IG group and 93.1±12.3 ng/ml in the GDM group (p<0.01 for GDM vs control subjects). There was a positive correlation between visfatin and fasting insulin (r=0.38, p=0.007) and insulin at 120 min of the OGTT (r=0.39, p=0.006). Conclusions/interpretation An increase in fasting visfatin, the levels of which correlate with both fasting and postglucose-load insulin concentrations, accompanies worsening glucose tolerance in the third trimester of pregnancy. However, the significance of these findings, and in particular the role of visfatin in the regulation of insulin sensitivity during pregnancy, remains to be elucidated.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 56%

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

et al. 2007

View full text Add to dashboard Cite

show abstract

“…These results are supported by Mazaki-Tovi et al [47] who obtained a comparable median visfatin concentration between normal and overweight pregnant women. On the other hand, lack of association between circulating visfatin and BMI was previously reported [49], although others reported positive [54] and negative [55] association between BMI and maternal visfatin. Other investigators could not demonstrate an association between visceral fat mass and plasma visfatin concentrations [56].…”

Section: Discussionmentioning

confidence: 86%

Maternal Leptin, Adiponectin, Resistin, Visfatin and Tumor Necrosis Factor-Alpha in Normal and Gestational Diabetes

Noureldeen

Qusti²,

Al‐Seeni³

et al. 2013

Ind J Clin Biochem

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a common medical complication associated with pregnancy. The present study evaluates the changes in maternal adipocytokines (leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha; TNF-a) in pregnancy complicated with GDM compared to normal pregnancy at 2nd and 3rd trimesters. The study included total number of 142 pregnant women classified into 4 groups: normal pregnancy (n = 33) and pregnancy with GDM (n = 24) both at 2nd trimester and normal pregnancy (n = 38) and GDM (n = 47) at 3rd trimester. Both GDM groups were significantly presented with elevated body mass index, fasting blood sugar and abnormal oral glucose tolerance test compared to their matched control. Results indicated reduction in maternal serum leptin and adiponectin in GDM compared to normal pregnancy at 3rd trimester. Elevated resistin and TNF-a were evident among pregnancy complicated with GDM at both tested trimesters. On the other hand, significant elevation in maternal visfatin was noted between GDM and matched control at 2nd trimester only. Significant increase in maternal leptin and visfatin and resistin was noted by advances in gestational period in healthy pregnancy. On the other hand, reduced adiponectin and elevated visfatin mean values were noticed in GDM at 3rd compared to 2nd trimester. It could be concluded that increased insulin resistance accompanies GDM is associated with suppressed leptin and adiponectin and increased resistin and TNF-a which might suggest their involvement in the development of GDM.

show abstract

“…86 In contrast, the measurement of visfatin/PBEF in women with gestational diabetes indicated that this condition was characterized by lower circulating concentrations of the factor. 87 A genomic investigation revealed that variants in promoter sequence correlate with type-2 diabetes but not with measures of adiposity, 88 whereas a second study indicated significant association of promoter variants with fasting insulin. 89 The identification of visfatin/PBEF as an adipokine and its implication in diabetes is far from being universally accepted.…”

Section: Does Adiponectin Play An Essential Role In Ovarian/ Uterine/mentioning

confidence: 99%

The ‘beneficial’ adipokines in reproduction and fertility

et al. 2007

View full text Add to dashboard Cite

The objective of this study was to review the available information on the signaling proteins produced by adipose tissue in the context of their role in regulating reproductive processes, including ovarian and uterine function. It is well known that both obesity and excessive leanness are associated with reproductive dysfunction. Adipokines are cytokines predominately or exclusively expressed by adipose tissue that circulate and affect target tissues. Four known adipokines, adiponectin, visfatin/ PBEF, omentin and vaspin, all increase tissue sensitivity to insulin, and are thus described as 'beneficial'. There is strong support for a role for adiponectin in the function of the ovary and placenta. There is evidence for direct effects of this adipokine on the late stages of folliculogenesis, and additive interactions of adiponectin with insulin and gonadotropins in inducing periovulatory changes in ovarian follicles. In addition, clinical and genomic studies associate hypoadiponectinemia with obesity-related reproductive disorders, including the polycystic ovarian syndrome. The roles for visfatin/PBEF, omentin and vaspin in reproduction remain to be established. The conclusion thus drawn is that the expression of insulin-sensitizing adipokines varies with adipose abundance. These adipokines have demonstrated both the potential effects on ovarian function and the possible effects on the formation of the placenta, acting through multiple mechanisms.

show abstract

Decreased Plsma Visfatin Concentrations in Women With Gestational Diabetes Mellitus

Abstract: Our results show that there are decreased concentrations of plasma visfatin in gestational diabetes mellitus subjects and this may indicate that visfatin plays a role in the pathogenesis of gestational diabetes mellitus. However, further experiments are needed to clarify this role.

Cited by 112 publications

References 12 publications

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Maternal Leptin, Adiponectin, Resistin, Visfatin and Tumor Necrosis Factor-Alpha in Normal and Gestational Diabetes

The ‘beneficial’ adipokines in reproduction and fertility

Contact Info

Product

Resources

About